BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587

Reuters02-24

Feb 24 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:

ATEA PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS SUPPORTING FIRST-IN-CLASS POTENTIAL OF AT-587 FOR TREATMENT OF HEPATITIS E VIRUS AT CROI 2026

Source text: ID:nGNX80b25W

Further company coverage: AVIR.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613716315?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613716315","market":"fut","top_or_hot":-1,"title":"BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Atea Pharmaceuticals Inc <span>AVIR.O</span>:</p><ul><li><p>ATEA PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS SUPPORTING FIRST-IN-CLASS POTENTIAL OF AT-587 FOR TREATMENT OF HEPATITIS E VIRUS AT CROI 2026</p></li></ul><p>Source text: <span>ID:nGNX80b25W</span></p><p>Further company coverage: <span>AVIR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Atea Pharmaceuticals Inc <span>AVIR.O</span>:</p><ul><li><p>ATEA PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS SUPPORTING FIRST-IN-CLASS POTENTIAL OF AT-587 FOR TREATMENT OF HEPATITIS E VIRUS AT CROI 2026</p></li></ul><p>Source text: <span>ID:nGNX80b25W</span></p><p>Further company coverage: <span>AVIR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVIR","symbol_name":"Atea Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA9YVBZZ:1","article_id":"2613716315","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613716315","pubTimestamp":1771935292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587Feb 24 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:ATEA PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS SUPPORTING FIRST-IN-CLASS POTENTIA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVIR":"Atea Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"简介-Atea Pharmaceuticals公布At-587的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVIR":0.9},"content_text":"BRIEF-Atea Pharmaceuticals Presents Preclinical Results Of At-587Feb 24 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:ATEA PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS SUPPORTING FIRST-IN-CLASS POTENTIAL OF AT-587 FOR TREATMENT OF HEPATITIS E VIRUS AT CROI 2026Source text: ID:nGNX80b25WFurther company coverage: AVIR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613716315","isCrawlerRequest":true}